Media.Player

Use of Calcium Binding Proteins to Improve Cardiac Contractile Function

詳細技術說明

The current treatment of heart failure is often heart transplantation. UCSD researchers have developed an alternative treatment for heart failure by regulating cytostolic calcium fluxes, in order to improve contractile function. Calcium regulation is achieved by enhancing the expression of a calcium binding protein in cardiac myocytes. In a diabetic mouse model for heart failure, overexpression of the calcium binding protein by adenoviral gene transfer dramatically rescued the abnormal contractile function in the diabetic heart. A specific application of the invention is the treatment of diabetic cardiomyopathy.

*Abstract

None

*IP Issue Date

Aug 30, 2011

*Principal Investigation

Name: Darrell Belke

Department:

Name: Wolfgang Dillmann

Department:

Name: Bernd Gloss

Department:

Name: Jorge Suarez

Department:

附加資料

Patent Number: US8007778B2
Application Number: US2003562524A
Inventor: Dillmann, Wolfgang H. | Suarez, Jorge | Belke, Darrell | Gloss, Bernd
Priority Date: 1 Jul 2003
Priority Number: US8007778B2
Application Date: 13 Sep 2006
Publication Date: 30 Aug 2011
IPC Current: A61K004800 | A01N006300 | C12Q000168
US Class: 4240931 | 43500617 | 514044R | 435006
Assignee Applicant: The Regents of the University of California
Title: Use of calcium binding proteins to improve cardiac contractile function
Usefulness: Use of calcium binding proteins to improve cardiac contractile function
Summary: Altering the expression of sorcin in the heart is used for increasing cardiac contractile function in a subject and administering an adenoviral vector encoding sorcin to a subject, where the sorcin is expressed, is useful for treating or preventing heart failure. Monitoring a therapeutic regimen for treating a subject having heart failure comprises determining a change in sorcin expression during therapy. Comparing the sorcin expression in a test sample from a subject with the sorcin expression in a corresponding normal sample, where a difference in sorcin expression in the test sample as compared to the sorcin expression in the normal sample is diagnostic of a cardiac contractile function associated disorder in the subject (All claimed).
Novelty: Increasing cardiac contractile function in a subject comprises altering the expression of sorcin in the heart, useful in regulating myocardial contraction and heart function and treating heart failure

主要類別

診斷/治療

細分類別

其他疾病

申請號碼

8007778

其他

Additional Technologies by these Inventors

• Treatment for Diabetic Cardiomyopathy

Tech ID/UC Case

19647/2002-225-0

Related Cases

2002-225-0

國家/地區

美國